Lifecore Biomedical Inc
NASDAQ:LFCR

Watchlist Manager
Lifecore Biomedical Inc Logo
Lifecore Biomedical Inc
NASDAQ:LFCR
Watchlist
Price: 7.67 USD 0.92%
Market Cap: 282.5m USD
Have any thoughts about
Lifecore Biomedical Inc?
Write Note

Lifecore Biomedical Inc
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lifecore Biomedical Inc
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Lifecore Biomedical Inc
NASDAQ:LFCR
Net Issuance of Debt
$1.6m
CAGR 3-Years
N/A
CAGR 5-Years
-55%
CAGR 10-Years
39%
Hershey Co
NYSE:HSY
Net Issuance of Debt
$376.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
General Mills Inc
NYSE:GIS
Net Issuance of Debt
$2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
0%
Kellogg Co
NYSE:K
Net Issuance of Debt
-$1.3B
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Kraft Heinz Co
NASDAQ:KHC
Net Issuance of Debt
-$38m
CAGR 3-Years
80%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Mondelez International Inc
NASDAQ:MDLZ
Net Issuance of Debt
-$837m
CAGR 3-Years
-28%
CAGR 5-Years
-18%
CAGR 10-Years
11%
No Stocks Found

Lifecore Biomedical Inc
Glance View

Market Cap
282.5m USD
Industry
Food Products

Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.

LFCR Intrinsic Value
10.95 USD
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Lifecore Biomedical Inc's Net Issuance of Debt?
Net Issuance of Debt
1.6m USD

Based on the financial report for Aug 25, 2024, Lifecore Biomedical Inc's Net Issuance of Debt amounts to 1.6m USD.

What is Lifecore Biomedical Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
39%

Over the last year, the Net Issuance of Debt growth was 13%.

Back to Top